Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ENTX vs ITRM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–1 Matrix Metrics)

ENTX Overall Winner 6-Pillar Tally: ENTX 3 – 1 ITRM (2 Tie) Matrix Metrics: ENTX 5 – 1 ITRM

As of Nov 20, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 47.5/100 (HOLD) at $3.31 (N/M Forward P/E, 0.0% operating margin), whereas ITRM carries 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin).

  • Composite vs. Pillar Nuance: While ITRM currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (5–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1982.3% operating margin) and revenue trajectory (-100.0% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2); meanwhile ITRM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTX vs ITRM
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.31
+0.76% 1D
Market Cap $571.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 53% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 52.0 Fund 49.0 Flow 72.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 61
RSI-14: 61.2 · SMA20: $3.13 · SMA50: $2.93
ITRM NASDAQ
Iterum Therapeutics plc Ordinary Share
Pharmaceutical Preparations
$0.03
-57.39% 1D
Market Cap $3.8M
TTM Revenue $390,000
Forward P/E N/M
Beta / 30D Vol 1.61β · 508% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 75.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.9%), weak momentum, RSI 26
RSI-14: 25.9 · SMA20: $0.15 · SMA50: $0.23

6-Pillar Scorecard Institutional Category Breakdown (ENTX 3 – 1 ITRM)

Columns: Metric · ENTX · ITRM
1. Valuation Multiples ITRM
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 9.6x
2. Growth & Scale Tie
Revenue Growth (YoY) -100.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $390,000
Market Cap $571.2M $3.8M
3. Profitability & Quality ENTX
Gross Margin N/A 29.7%
Operating Margin 0.0% -1982.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -20.3% -555.7%
4. Balance Sheet & Cash Flow ENTX
Cash Generation (TTM) -$16M -$19M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $265M Net Cash -555.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 116.0% (33rd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTX (5) vs ITRM (1)
Institutional Metric ENTX ITRM Criterion Row Edge
Market Capitalization
Scale
$571.2M $3.8M Larger Scale ENTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% -100.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% -1982.3% Higher Margin ENTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-20.3% -555.7% Higher ROE ENTX
52-Week Range Position
Momentum
73% ($1–$4) 0% ($0–$1) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
0.92β · 53% Vol 1.61β · 508% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 50.5 / 100 (HOLD) Higher Composite ITRM
Trailing 12M Revenue (USD)
Operating Scale
N/A $390,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 29.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 9.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M ($265M Net Cash) -$19M EBITDA (-555.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENTX +70.4 pp
ENTX: -18.98% · ITRM: -89.38%
3M Horizon ENTX +51.29 pp
ENTX: -38.33% · ITRM: -89.62%
6M Horizon ENTX +34.1 pp
ENTX: -58.11% · ITRM: -92.21%
1Y Horizon ENTX +34.1 pp
ENTX: -58.11% · ITRM: -92.21%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENTX vs ITRM. Trailing 12-month operating profitability (ENTX 0.0% vs ITRM -1982.3%) and valuation multiples (ENTX N/M vs ITRM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ENTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-20.3% · N/M
ITRM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$390,000
Gross Margin29.7%
Op. Margin-1982.3%
ROE / Fwd P/E-555.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTX CONSOLIDATION
83d in phase · OBV NEUTRAL
Current IV 116.0%
IV Percentile 33rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ITRM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ITRM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $571.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ITRM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8M market capitalization and -1982.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTX vs ITRM Key Questions & Quantitative Answers

As of Nov 20, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 47.5/100 (HOLD) at $3.31 (N/M Forward P/E, 0.0% operating margin), whereas ITRM carries 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin). Composite vs. Pillar Nuance: While ITRM currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (5–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1982.3% operating margin) and revenue trajectory (-100.0% vs. -100.0% YoY). Technical & Structure Timing Caution: ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2); meanwhile ITRM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ENTX and ITRM split Growth & Scale metrics: ENTX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ITRM at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $390,000 TTM revenue (29.7% gross margin, -1982.3% operating margin). On trailing 12-month operating scale, ENTX generates N/A in USD-normalized revenue versus $390,000 for ITRM. In operating R&D and SG&A reinvestment, ENTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ITRM.

ITRM screens cheaper on headline valuation multiples. ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ITRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTX (-20.3% ROE) versus ITRM (-555.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTX carries 116.0% implied volatility (33rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 53% Vol realized risk). By comparison, ITRM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 508% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.